为您找到"
&ad
"相关结果约100,000,000个
Agora is a results explorer for the AMP-AD consortium. It provides visual explorers of multi-omic data from human brain samples and shares a list of nascent therapeutic targets for AD.
Accelerating Alzheimer's Research and Drug Development The Accelerating Medicines Partnership® Program for Alzheimer's Disease (AMP® AD) is a precompetitive partnership among government, industry, and nonprofit organizations to transform the current model for developing new diagnostics and treatments for Alzheimer's disease.
The Accelerating Medicines Partnership- Alzheimer's Disease Target Discovery and Preclinical Validation (AMP-AD) has supported the generation of whole genome data from three studies: the MAYO RNAseq Study, the Mount Sinai Brain Bank, and the ROSMAP study. The Genome Center for AD (GCAD) has partnered with the investigators of these studies…
Agora hosts high-dimensional human transcriptomic, proteomic, and metabolomic evidence for whether or not genes are associated with Alzheimer's Disease (AD). Agora also contains a list of over 900 nascent AD drug targets that were nominated by researchers from the National Institute on Aging's AMP-AD consortium and TREAT-AD centers, as well ...
AMP AD 2.0 is a precompetitive public-private partnership that will enable precision medicine research for Alzheimer's disease through deep and longitudinal molecular analyses across diverse populations to provide insights that will accelerate the development of therapies for Alzheimer's disease.
The AD Knowledge Portal was developed as part of the Accelerating Medicines Partnership in Alzheimer's Disease (AMP‐AD) program between the National Institutes of Health (NIH) and several nonprofit organizations and pharmaceutical companies. Powered by Synapse.
Previously known as the AMP-AD Knowledge Portal, the site initially was a repository for the NIA's Accelerating Medicines Partnership - Alzheimer's Disease (AMP-AD) Consortium. The site has recently expanded scope to include data from three additional NIA-funded consortia with complementary goals. The addition of a user-friendly web interface has made it easier for qualified researchers ...
The AMP-AD Target Discovery and Preclinical Validation Project aims to reduce the time between the discovery of potential drug targets and the development of new drugs for Alzheimer's disease (AD) treatment and prevention (RFA-AG-18-013).
The Accelerating Medicines Partnership® Program for Alzheimer's Disease (AMP® AD) program is a precompetitive partnership among government, industry, and nonprofit organizations to transform the current model for developing new diagnostics and treatments for Alzheimer's disease. The goal of the second iteration of this transformative partnership is to expand the open-science, precompetitive ...
Faster mobile landing pages typically reduce website abandonment and bounce rates, which can increase conversions and improve your overall ad performance. For a simple way to speed up load times, build your landing page with AMP. This article explains how to use AMP with Google Ads.